chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome
Conditions
Interventions
indigo naturalis 2g/day for oral administration is be administered daily in 2 divided doses during 8weeks.
Sponsors
Keio University Gastroenterology and Hepatology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) The patients were diagnosed chronic enteropathy associated with SLCO2A1 gene or Cronkhite-Canada syndrome. 2)The patients were 20~69 years old. 3)The patients who were obtained the consent. in this study.
Exclusion criteria
Exclusion criteria: The patients who meet the following criteria are excluded. 1 The patients have stricture of the digestive tract. 2 The patients plans to undergo surgery. 3 The patients have severe infection. 4 The patients have severe heart failure. 5 The patients have serum Creatinine above 2. 6 The patients have T.Bil above 2.0, AST above 50, or ALT above 50. 7 The patients have malignancy or past history of malignancy. 8 The patients have neuropsychiatric disorder. 9 Women who are or may be pregnant, nursing women and woman who desire to bear children. 10 Inappropriate patients by doctor's judgement. 11 The patients who received other traditional chinese medicine inside 2 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome after 24weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| efficacy of indigo naturalis for chronic enteropathy associated with SLCO2A1 and Cronkhite-Canada syndrome (endoscopic evaluation, clinical symptoms, Hb levels and serum Alb levels after 8 and 24 weeks) | — |
Countries
Japan
Contacts
Public ContactMakoto Naganuma
Keio University Gastroenterology and Hepatology
Outcome results
None listed